Edition:
India

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
23 Feb 2018
Change (% chg)

$0.05 (+4.59%)
Prev Close
$1.09
Open
$1.10
Day's High
$1.15
Day's Low
$1.10
Volume
80,508
Avg. Vol
54,700
52-wk High
$3.88
52-wk Low
$0.95

Select another date:

Sat, Feb 17 2018

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage:

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

BRIEF-Onconova Therapeutics prices public offering

* Onconova Therapeutics announces pricing of public offering of common stock

BRIEF-Onconova Therapeutics reports Q3 revenue $100,000

* Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

Select another date: